The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Microbiome in pharma: bacteriophage therapy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
Bacteriophage therapy is a key innovation area in microbiome
Bacteriophage therapy, also known as phage therapy, is a type of treatment that uses naturally occurring viruses called bacteriophages to target and kill harmful bacteria in the body. Bacteriophages are specific to the type of bacteria they target, making them a potential alternative to antibiotics and a promising option for treating bacterial infections.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 20+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of bacteriophage therapy.
Key players in bacteriophage therapy – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to bacteriophage therapy
| Company | Total patents (2010 - 2022) | Premium intelligence on the world's largest companies |
| iNtRON Biotechnology | 177 | Unlock Company Profile |
| Snipr Technologies | 53 | Unlock Company Profile |
| CJ | 46 | Unlock Company Profile |
| Phico Therapeutics | 34 | Unlock Company Profile |
| Pherecydes Pharma | 23 | Unlock Company Profile |
| Industria Tecnica Farmaceutica | 23 | Unlock Company Profile |
| Armata Pharmaceuticals | 21 | Unlock Company Profile |
| Laboratory Corp of America | 17 | Unlock Company Profile |
| Eligo Bioscience | 16 | Unlock Company Profile |
| GSK | 14 | Unlock Company Profile |
| TechnoPhage | 13 | Unlock Company Profile |
| Micreos | 11 | Unlock Company Profile |
| Locus Biosciences | 10 | Unlock Company Profile |
| SNIPR Biome | 8 | Unlock Company Profile |
| Pastoral Greenhouse Gas Research | 7 | Unlock Company Profile |
| Nestle | 6 | Unlock Company Profile |
| GangaGen | 4 | Unlock Company Profile |
| Royal DSM | 3 | Unlock Company Profile |
| Can Technologies | 2 | Unlock Company Profile |
| Pastoral Greenhouse Research | 2 | Unlock Company Profile |
| PHI Therapeutics | 1 | Unlock Company Profile |
| Intralytix | 1 | Unlock Company Profile |
| Teagasc | 1 | Unlock Company Profile |
| Inst Animal Science & Veterinary Medicine Shandong | 1 | Unlock Company Profile |
Source: GlobalData Patent Analytics
Intron Biotechnology (Intron Bio) is one of the leading patent filers in bacteriophage therapy. The drug development company focuses on biotechnology and genetic engineering, which can be used to treat human diseases. Its technologies include endolysin, bacteriophage, and biofilm. The company's endolysin technology is an antibiotic substance that destroys the cell walls of bacteria. The company also develops infectious disease drugs. Snipr Biome and CJ are some of the other key patent filers in bacteriophage therapy.
In terms of application diversity, Intralytix leads the pack, while iNtRON Biotechnology and Micreos stood in the second and third positions, respectively. By means of geographic reach, Phico Therapeutics held the top position, followed by Industria Tecnica Farmaceutica and GSK.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Microbiome.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
